Meag Munich Ergo Kapitalanlagegesellschaft MBH Grows Position in Amgen, Inc. (AMGN)
Meag Munich Ergo Kapitalanlagegesellschaft MBH boosted its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 43.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 72,311 shares of the medical research company’s stock after purchasing an additional 21,798 shares during the period. Meag Munich Ergo Kapitalanlagegesellschaft MBH’s holdings in Amgen were worth $12,747,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in AMGN. Baker Ellis Asset Management LLC acquired a new stake in shares of Amgen in the third quarter worth about $108,000. Phocas Financial Corp. acquired a new stake in shares of Amgen in the second quarter worth about $110,000. Jackson Grant Investment Advisers Inc. lifted its position in shares of Amgen by 0.8% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after buying an additional 5 shares during the last quarter. Omnia Family Wealth LLC lifted its position in shares of Amgen by 25.3% during the 2nd quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock worth $125,000 after purchasing an additional 147 shares during the last quarter. Finally, Horan Capital Advisors LLC. acquired a new position in shares of Amgen during the 3rd quarter worth about $150,000. 78.61% of the stock is owned by hedge funds and other institutional investors.
AMGN has been the subject of several research analyst reports. BidaskClub raised Amgen from a “strong sell” rating to a “sell” rating in a research report on Saturday, December 2nd. Vetr raised Amgen from a “sell” rating to a “hold” rating and set a $181.60 price objective for the company in a research report on Tuesday, February 27th. Oppenheimer reissued a “buy” rating and set a $205.00 price objective on shares of Amgen in a research report on Tuesday, January 30th. Piper Jaffray Companies reissued a “buy” rating on shares of Amgen in a research report on Tuesday, January 2nd. Finally, Goldman Sachs Group cut Amgen from a “conviction-buy” rating to a “buy” rating in a research report on Friday, December 15th. Sixteen equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $191.72.
Shares of Amgen, Inc. (AMGN) opened at $185.08 on Monday. Amgen, Inc. has a 12 month low of $152.16 and a 12 month high of $201.23. The firm has a market capitalization of $133,361.66, a P/E ratio of 14.71, a PEG ratio of 2.21 and a beta of 1.37. The company has a quick ratio of 5.17, a current ratio of 5.49 and a debt-to-equity ratio of 1.35.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, February 1st. The medical research company reported $2.89 earnings per share for the quarter, missing the consensus estimate of $3.03 by ($0.14). Amgen had a net margin of 8.66% and a return on equity of 30.87%. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.84 billion. During the same quarter in the prior year, the company posted $2.89 earnings per share. The company’s revenue for the quarter was down 2.7% on a year-over-year basis. sell-side analysts predict that Amgen, Inc. will post 13.21 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be paid a $1.32 dividend. This is a positive change from Amgen’s previous quarterly dividend of $1.15. This represents a $5.28 annualized dividend and a dividend yield of 2.85%. The ex-dividend date is Wednesday, February 14th. Amgen’s dividend payout ratio is currently 205.45%.
Amgen announced that its board has approved a share buyback program on Thursday, February 1st that allows the company to buyback $10.00 billion in outstanding shares. This buyback authorization allows the medical research company to repurchase shares of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board of directors believes its shares are undervalued.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.